Ube2s-KO 基因敲除小鼠

下单100%中奖,最高可得千元京东卡
复苏/繁育服务
产品名称

Ube2s-KO 基因敲除小鼠

产品编号

S-KO-15107

品系全称

C57BL/6JCya-Ube2sem1/Cya

品系背景

C57BL/6JCya

品系编号

KOCMP-77891-Ube2s-B6J-VA

品系状态

使用本品系发表的文献需注明: Ube2s-KO 基因敲除小鼠 mice (Strain S-KO-15107) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量

基本信息

基因研究概述

质控标准

基因
基因全称
ubiquitin-conjugating enzyme E2S
基因别称
0910001J09Rik,6720465F12Rik,E2-EPF
染色体号
Chr 7 (Mouse)
转录本 ID
NCBI: NM_133777 | Ensembl: ENSMUST00000079496
修饰方式
全身性基因敲除
靶向范围
Exon 1~4
敲除长度
~4.0 kb
品系说明
该品系是基于策略设计时的数据库信息制作而成,建议您在购买前查询最新的数据库和相关文献,以获取最准确的表型信息。
表型提示
MGI:1925141Mice homozygous for a null allele display reduced susceptibility to viral infection, female infertility, and arrest of female meiosis.
Ube2s,即E2泛素结合酶S,是一种在泛素化过程中发挥重要作用的酶。泛素化是一种重要的蛋白质翻译后修饰过程,通过将泛素分子附着到目标蛋白质上,可以调节蛋白质的稳定性、定位、功能和活性。Ube2s属于E2酶家族,负责将泛素分子从E1活化酶转移到E3连接酶识别的底物蛋白质上,从而启动泛素化过程。泛素化在多种生物学过程中发挥着关键作用,包括细胞周期调控、DNA损伤修复、信号转导、蛋白质降解和细胞凋亡等。

在癌症研究中,Ube2s的表达水平和活性与多种癌症的发生和发展密切相关。多项研究表明,Ube2s在多种癌症中表达上调,包括膀胱癌、肝癌、卵巢癌和肺癌等。Ube2s通过多种机制促进肿瘤的发生和发展,包括调节细胞代谢、抑制细胞凋亡、促进细胞迁移和侵袭等。

在膀胱癌中,Ube2s与TRIM21相互作用,通过K11连接的泛素化降解LPP,从而促进膀胱癌的淋巴转移[1]。在肝癌中,Ube2s通过增强VHL的E3酶非依赖性泛素化,间接稳定HIF-1α蛋白水平,从而促进肝癌细胞的糖酵解和增殖[2]。在卵巢癌中,Ube2s通过激活PI3K/AKT/mTOR信号通路抑制自噬,导致顺铂耐药性[3]。在肺癌中,Ube2s通过VHL/HIF-1α和VHL/JAK2/STAT3信号通路增强恶性表型,并降低对索拉非尼的敏感性[4]。此外,Ube2s在肝癌中还通过促进PI3K/AKT/mTOR信号通路调节细胞周期和凋亡,促进卵巢癌的发展[5]。在肝细胞癌中,Ube2s与TRIM28相互作用,通过泛素化降解p27,加速细胞周期,促进肝细胞癌的发展[6]。在肺腺癌中,Ube2s通过结合IκBα激活NF-κB信号通路,促进肺腺癌细胞的转移[7]。此外,Ube2s还通过稳定β-catenin激活HIF-1α信号通路,保护心肌免受缺血再灌注损伤[8]。Ube2s的表达与肿瘤相关巨噬细胞的浸润密切相关,可能成为泛癌的潜在诊断和预后标志物[9]。在肺腺癌中,Ube2s的过表达与较差的预后相关,其沉默导致细胞增殖、集落形成减少和凋亡增加[10]。

综上所述,Ube2s是一种重要的E2泛素结合酶,在多种癌症的发生和发展中发挥着关键作用。Ube2s通过多种机制促进肿瘤的发生和发展,包括调节细胞代谢、抑制细胞凋亡、促进细胞迁移和侵袭等。Ube2s的研究有助于深入理解泛素化在癌症发生和发展中的作用机制,为癌症的治疗和预防提供新的思路和策略。

参考文献:
1. Xiao, Kanghua, Peng, Shengmeng, Lu, Junlin, Chen, Xu, Lin, Tianxin. 2023. UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer. In Cell death & disease, 14, 408. doi:10.1038/s41419-023-05938-2. https://pubmed.ncbi.nlm.nih.gov/37422473/
2. Zhang, Renyu, Li, Can, Zhang, Shuai, Chen, Zhinan, Bian, Huijie. 2024. UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL. In Clinical and molecular hepatology, 30, 771-792. doi:10.3350/cmh.2024.0236. https://pubmed.ncbi.nlm.nih.gov/38915206/
3. Zhang, Mengjun, Wang, Jialin, Guo, Yan, Yue, Haodi, Zhang, Lindong. 2023. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer. In Journal of ovarian research, 16, 240. doi:10.1186/s13048-023-01314-y. https://pubmed.ncbi.nlm.nih.gov/38115063/
4. Wu, Junyi, Xu, Xiangjie, Wu, Shasha, Wu, Junhua, Jiang, Chunping. 2023. UBE2S promotes malignant properties via VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma. In Cancer medicine, 12, 18078-18097. doi:10.1002/cam4.6431. https://pubmed.ncbi.nlm.nih.gov/37563971/
5. Zhang, Mengjun, Liu, Yuan, Yin, Yue, Li, Fei, Chen, Xiuwei. 2022. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis. In Molecular medicine (Cambridge, Mass.), 28, 62. doi:10.1186/s10020-022-00489-2. https://pubmed.ncbi.nlm.nih.gov/35658829/
6. Zhang, Ren-Yu, Liu, Ze-Kun, Wei, Ding, Chen, Zhi-Nan, Bian, Huijie. 2021. UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development. In Signal transduction and targeted therapy, 6, 64. doi:10.1038/s41392-020-00432-z. https://pubmed.ncbi.nlm.nih.gov/33589597/
7. Ho, Jhih-Yun, Lu, Hsin-Ying, Cheng, Hsing-Hsien, Lee, Yu-Lin Amy, Cheng, Chia-Hsiung. 2021. UBE2S activates NF-κB signaling by binding with IκBα and promotes metastasis of lung adenocarcinoma cells. In Cellular oncology (Dordrecht, Netherlands), 44, 1325-1338. doi:10.1007/s13402-021-00639-4. https://pubmed.ncbi.nlm.nih.gov/34582005/
8. Chen, Xi, Wang, Chiyao, Yang, Pei, Shi, Lei, Wang, Haiyan. 2020. Ube2s-stabilized β-catenin protects against myocardial ischemia/reperfusion injury by activating HIF-1α signaling. In Aging, 12, 5716-5732. doi:10.18632/aging.102960. https://pubmed.ncbi.nlm.nih.gov/32250966/
9. Yue, Haodi, Wang, Jialin, Hou, Siyu, Zhang, Mengjun. 2023. As a potential predictor of pan-cancer, UBE2S is related to tumor-associated macrophage infiltration. In Future oncology (London, England), 19, 1973-1990. doi:10.2217/fon-2023-0086. https://pubmed.ncbi.nlm.nih.gov/37791471/
10. Liu, Zhi, Xu, Lijun. . UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells. In BMB reports, 51, 642-647. doi:. https://pubmed.ncbi.nlm.nih.gov/30545437/